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Abstract
The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic 
hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for 
International Blood and Marrow Transplant Research (CIBMTR) we compared the outcomes of 
patients who had EMD of AML at any time prior to transplant to a cohort of AML patients 
without EMD. We reviewed data AML from 9,797 patients including 814 with EMD from 310 
reporting centers and 44 different countries who underwent alloHCT between and 1995–2010. The 
primary outcome was overall survival (OS) after alloHCT. Secondary outcomes included 
leukemia-free survival (LFS), relapse rate, and treatment-related mortality (TRM). In a 
multivariate analysis, the presence of EMD did not affect either OS (HR 1.00, 95% CI 0.91–1.09), 
LFS (0.98, 0.89–1.09), TRM (RR 0.92, 95% CI 0.80–1.16, p=0.23) or relapse (RR =1.03, 95% CI, 
0.92–1.16; p=0.62). Furthermore, the outcome of patients with EMD was not influenced by the 
location, timing of EMD, or intensity of conditioning regimen. The presence of EMD in AML 
does not affect transplant outcomes and should not be viewed as an independent adverse 
prognostic feature.
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Introduction
Extramedullary disease (EMD) in AML refers to disease found in organs or tissue outside 
the blood or bone marrow. The most common manifestations of EMD include myeloid 
sarcomas, leukemia cutis, and meningeal leukemia. Although the exact frequency is 
unknown, EMD has been estimated to occur in 3 – 8% of patients with AML, and has been 
reported to be more common in patients with core-binding factor leukemia, FAB 
M2/M4/M5, high WBC count and increased age.1 Historically, the presence of EMD has 
been considered a poor prognostic feature in AML.2 However, the impact of EMD may 
depend on the site of EMD as well as cytogenetic and molecular features. In adult patients 
with t(8:21), complete remission (CR) rates (50% vs 92%) and overall survival (OS) (5.4 vs 
59.5 months) were markedly worse in patients with EMD treated with standard 7+3 
regimens.3 In a retrospective analysis of 434 Japanese patients with AML, myeloid 
sarcomas were associated with higher relapse rate and lower disease-free survival (DFS).4
Due to its potent antitumor effects, it has been suggested that allogeneic hematopoietic cell 
transplantation (alloHCT) could overcome the potential poor prognostic impact of EMD in 
AML. However, data supporting this approach are limited. A retrospective study from the 
Société Francaise de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) registry of 51 
patients with myeloid sarcoma who underwent alloSCT demonstrated an OS of 36% at 5 
years confirming that alloSCT is a valid therapeutic option.5 Isolated EMD relapses are 
common following alloHCT in patients with AML indicating a relative lack of graft vs. 
leukemia effect in EMD sites.6 Furthermore, reduced intensity conditioning (RIC) regimens, 
T cell depleted grafts, or non-total body irradiation (TBI) based conditioning regimens have 
been associated with higher rates of EMD relapse and may reduce the effectiveness of 
alloHCT in AML with EMD disease.7–10
Because a prospective study to determine the impact of alloHCT for AML with EMD is not 
feasible, the Center for International Blood and Marrow Transplant Research (CIMBTR) 
database offers a comprehensive dataset to identify factors that influence the outcome of 
alloHCT for AML with EMD. In this study, we compared the outcomes of patients who had 
EMD of AML at any time prior to transplant to a cohort of AML patients without EMD. We 
also examined disease-, treatment-, and transplant-related characteristics that affected the 
outcomes of patients with EMD.
Patients and methods
Data source
The CIBMTR, a voluntary working group of more than 500 transplant centers worldwide, 
contribute data on consecutive allogeneic hematopoietic cell transplants to a statistical center 
housed both at the Medical College of Wisconsin (Milwaukee, WI) and the National 
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Marrow Donor Program (Minneapolis, MN). Observational studies conducted by CIBMTR 
are performed with a waiver of informed consent and in compliance with Health Insurance 
Portability and Accountability Act regulations as determined by the Institutional Review 
Board and the Privacy Officer of the Medical College of Wisconsin.
Patient selection
The study population consists of AML patients between 18–70 years of age who underwent 
bone marrow or peripheral blood alloHCT from either an HLA-identical sibling or unrelated 
donor between 1995 and 2010. Patients with acute promyelocytic leukemia were excluded.
The site of EMD was determined by the reporting center in one of four categories: CNS, soft 
tissue, testes, or other. The “other” category was further subdivided into clinically relevant 
categories such as “skin” and “liver/spleen”. Pathologic or radiographic confirmation of EM 
disease was not required. Cytogenetics were classified according to SWOG/ECOG 
criteria.11 Conditioning regimens were classified as myeloablative (MA), reduced-intensity 
(RIC), or non-myeloablative (NMA).12, 13 CIBMTR classifications of unrelated donor 
(URD) matching were used to define well-matched, partially matched or mismatched 
categories.
Study end points and definitions
The primary outcome was overall survival (OS) after alloHCT (defined as the time from 
transplantation to death). Secondary end points included leukemia-free survival (LFS), 
relapse rate, and treatment-related (non-relapse) mortality (TRM; defined as any death in the 
first 28 days after transplantation or any death after day 28 in continuous remission), 
incidence of grade II–IV acute graft-versus-host disease (GVHD) and the presence of 
chronic GVHD. Surviving patients were censored at the time of last contact.
Statistical analysis
Patient-, disease- and treatment-related factors were compared between EMD and non-EMD 
groups using the Chi-Square tests for categorical and Mann-Whitney test for continuous 
variables. The probability of LFS and OS were calculated using the Kaplan-Meier estimator, 
with the variance estimated by Greenwood’s formula. Values for other endpoints were 
calculated using cumulative incidence curves to accommodate competing risks.14
EMD and non-EMD groups were compared using proportional hazards regression models. 
Risk factors with significant level of p<0.05 in stepwise model building procedures were 
included in the outcome models. Potential interactions between the main effect (EMD 




A total of 9,797 patients were identified from 310 reporting centers and 44 different 
countries: 814 with EMD prior to alloHCT (EMD group) and 8,983 without EMD pre-
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transplant (non-EMD group). The median follow-up of survivors was 58 months (range, 3–
191 months) for the EMD group and 60 months (range, 3–194 months) for the non-EMD 
group.
Table 1 lists patient-, disease-, treatment-, and transplant-related variables for all patients. 
Patients with EMD tended to be younger (median age of 42 vs. 46 years, p < 0.001), were 
more likely to have a monocytic subtype (FAB M4-M5, 46 vs 29%, p < 0.001), and a higher 
initial WBC at diagnosis (22 vs 9, p<0.001). The most common site of EMD was CNS 
involvement (n=293, 35%). For other sites, 155 (19%) had skin-only and 112 (14%) 
possessed lymph node-only EMD. An additional 69 (8%) reported multiple sites of EMD.
Transplant conditioning regimens differed between the two groups. In the EMD group, 82% 
received a MA preparative regimen with 47% receiving a MA conditioning with total body 
irradiation compared to 75% and 35% respectively in the non-EMD group (p<0.001 for both 
comparisons). Disease status prior to conditioning also differed between the non-EMD and 
EMD groups: primary induction failure (PIF) 15% vs 12%, CR1 49% vs 37%, CR2 or 
beyond 20% vs 26%, active relapse 17% vs 24%, respectively (p < 0.001). The duration of 
first remission was shorter for subjects transplanted in CR2 in the EMD group vs the non-
EMD group, 9 vs 11 months (p < 0.001) with 32% having a CR1 duration of < 6 months 
compared to 19% (p < 0.001) in the non-EMD group.
Univariate analysis of outcomes
Comparisons of outcomes between the EMD and non-EMD groups are listed in Table 2. 
There were no significant differences in LFS or OS, the primary end-points of our study, 
between patients with and without EMD in univariate analysis (Figure 1, Table 2). The 5 
year LFS and OS for the EMD group was 33% (95%CI 30–37%) and 36% (95%CI 32–39%) 
respectively. The relapse rate in the EMD groups was significantly higher at 1 year (33% vs 
29%, p = 0.012) and 3 years (39% vs 34%, p = 0.022) post-transplant compared to the non-
EMD group. However, this risk was offset by lower rates of TRM post-transplant at 3 years 
(24% vs 29%, p = 0.009) and 5 years (26% vs 31%, p = 0.009) in the EMD group.
For the 61 patients who proceeded to transplant with active medullary and EMD, univariate 
analysis showed significantly higher 3-year relapse rate when compared to EMD group 
(62% vs 39%, p = <0.001), and significantly worse 3-year LFS (9% vs 37%, p = <0.001), 
and OS (10% vs 40%, p = <0.001). (Table 2).
Leukemia was the most common cause of death in the non-EMD group (42%) and EMD 
group (49%), followed by infection and GVHD (Supplemental Table 1). For all patients who 
relapsed after transplant, there were significant differences in the site of relapse post-
transplant (Supplemental Table 2). In the EMD group, 26% (14% EM site, 12% peripheral 
blood (PB)/bone marrow (BM) and EM site) of patients relapsed at extramedullary sites 
whereas only 9% (5% EM site, 4% PB/BM and EM site) of patients in the non-EMD group 
relapsed at extramedullary sites. For patients transplanted in ≥ CR2 or at relapse, 23% of the 
EM group relapsed solely at an EM site post-transplant and 18% relapsed at both medullary 
and EM sites.
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Multivariate analysis of outcomes
Because of the poor outcomes of subjects with both EMD and active marrow disease at the 
time of transplant, these patients were excluded from the multivariate analysis. Notably, the 
presence of EMD did not affect either OS (HR 1.00, 95% CI 0.91–1.09; p=0.91) or LFS 
(0.98, 0.89–1.09; p=0.74). In addition, differences in both TRM (RR 0.92, 95% CI 0.80–
1.06, p=0.23) and relapse (RR =1.03, 95% CI, 0.92–1.16; p=0.62) failed to retain their 
significance in the multivariate model (Table 4, Supplemental Table 4).
Outcome site of EMD disease or by onset of EMD
No significant differences were observed in the rate of relapse, (p=0.66, Figure 2) or OS 
based on by site of EMD (p=0.28, Table 3). We compared the outcomes of the 71 patients 
who had an isolated granulocytic sarcoma compared to the remaining 743 patients with both 
EMD and marrow involvement of their leukemia (Supplemental Table 3). We also examined 
the timing of EMD onset, whether EMD was present at the time of diagnosis or at the time 
of transplantation. Again, in each case, there was no difference in OS between these two 
groups. (Table 3)
Pretransplant conditioning
Because the GVL effect might be weaker in EM sites6, we also tested for any interaction 
between the presence of EMD and the intensity of the conditioning regimen on the risk of 
relapse which might confound our analysis. No interaction was identified between MA and 
RIC on the risk of relapse (P=0.1591). After MA conditioning, the relative risk of relapse 
was 1.09 (95% CI, 0.95–1.24; p=0.21) and for RIC was 0.89 (95% CI, 0.70–1.14; p=0.36).
Acute and chronic GVHD
At day 100, the incidence of grade 2 to 4 acute GVHD was similar between the EMD and 
non-EMD groups (35% vs 36%, p=0.60, Table 2). The incidence of chronic GVHD at 1-, 3-, 
and 5-years was also similar between the 2 groups.
Discussion
This analysis of 814 patients with EM involvement of AML represents the largest and most 
comprehensive analysis of alloHCT outcomes in this patient population. Historically, EMD 
has been viewed as a poor prognostic factor, although data supporting this position are 
limited. For other risk factors in AML such as a monosomal karyotype and FLT3-ITD, the 
adverse prognostic impact persists despite alloHCT.15, 16 Unexpectedly, when compared to 
a non-EMD cohort, we did not identify any impact of EMD itself on either survival, disease 
relapse, or treatment related mortality. In addition the location, timing of EMD, or intensity 
of conditioning regimen also did not affect transplant outcomes.
As with any large retrospective registry study, there are important limitations in our analysis. 
The presence and location of EMD was determined by the reporting center and did not 
require a confirmatory pathologic or radiographic diagnosis. This may result in 
underreporting of EMD in locations such as lymph nodes and deep soft tissue sites that can 
escape detection on routine clinical examination, and over reporting in areas such as the 
Goyal et al. Page 6













skin, where leukemia cutis may be confused with other dermatologic conditions. At the 
same time, this mirrors current clinical practice in which no guidelines or standards exist for 
the evaluation of EMD.
Because of the relative uncommon nature EMD, we are also unable to make meaningful 
conclusions about specific individual cytogenetic subtypes i.e. t(8:21) or MLL 
rearrangements, and more uncommon sites of EMD such as testicular involvement. 
Molecular genetics in AML is a rapidly evolving field and the CIBMTR dataset for AML is 
limited by lack of uniform molecular characterization of cases. For example, nucleophosmin 
mutations in cytogenetically normal AML confer a favorable prognosis and have been 
identified in 15% of isolated myeloid sarcomas though aberrant cytoplasmic localization of 
the protein by immunohistochemistry.17
Based on our analysis of the CIBMTR, we found that the presence of EMD is not an 
independent risk factor for relapse, DFS, or OS in patients undergoing alloHCT. 
Furthermore, the outcome of patients with EMD was not influenced by the location, timing 
of EMD, or intensity of conditioning regimen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Analysis of HCT outcome by EMD vs. no-EMD
Probability of overall survival (OS), leukemia free-survival (LFS) and cumulative incidence 
frequency (CIF) of treatment related mortality (TRM) and relapse
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Cumulative incidence of relapse based on anatomic location of EMD.
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Table 1
Characteristics of patients between 18 to 70 years of age who underwent allogeneic transplant for AML 
between 1995 and 2010 reported to the CIBMTR
Characteristics of patients No-extramedullary disease Extramedullary P-value
Number of patients 8983 814
Number of centers 299 178
Age, median (range) 46 (18–70) 42 (18–70) <0.001
Age in decades <0.001
 18–29 1533 (17) 199 (24)
 30–39 1599 (18) 164 (20)
 40–49 2311 (26) 206 (25)
 50–59 2364 (26) 186 (23)
 60–70 1176 (13) 59 (7)
Sex 0.03
 Male 4692 (52) 458 (56)
 Female 4291 (48) 356 (44)
Karnofsky score 0.01
 <90% 2877 (32) 301 (37)
 >=90% 5652 (63) 470 (58)
 Missing 454 (5) 43 (5)
Sub-disease <0.001
 M0-M1 1737 (19) 124 (15)
 M2 Myelocytic 2014 (22) 91 (11)
 M4-M5 2579 (29) 374 (46)
 M6 Erythroblastic 311 (3) 7 (<1)
 M7 Megakaryoblastic 137 (2) 12 (1)
 Granulocytic sarcoma with unknown subtype 0 71 (8)
 AML with t(8;21)(q22;q22)(AML1/ETO) 39 (<1) 8 (<1)
 AML with abnormal BM eosinophils (CBFb/MYH11) 37 (<1) 4 (<1)
 AML with multi-lineage dysplasia 530 (6) 21 (3)
 AML, other specified 250 (3) 36 (4)
 AML, subtype unknown 1349 (16) 66 (8)
White blood count at diagnosis, ×10^9/L <0.001
 Median (range) 9 (<1–1000) 22 (<1–600)
 <= 10 3998 (45) 253 (31)
 10 – 100 2965 (33) 334 (41)
 > 100 707 (8) 120 (15)
 Missing 1313 (15) 107 (13)
Cytogenetic abnormalities <0.001
 Favorable 555 (6) 72 (9)
 Intermediate 4129 (46) 407 (50)
 Poor 1752 (20) 140 (17)
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Characteristics of patients No-extramedullary disease Extramedullary P-value
 Missing 2547 (28) 195 (23)
Previous history of MDS <0.001
 No 7182 (80) 709 (87)
 Yes 1709 (19) 94 (12)
 Missing 92 (1) 11 (1)
Disease status prior to conditioning <0.001
 Primary induction failure 1313 (15) 97 (12)
 CR1 4367 (49) 305 (37)
 >=CR2 1773 (20) 214 (26)
 Relapse 1530 (17) 198 (24)
Extramedullary disease N/A
 Not present 8983 0
 At both diagnosis and transplant 0 60 (7)
 At diagnosis only 0 542 (67)
 At transplant only 0 159 (20)
 CNS leukemia present any time prior to conditioning 0 53 (7)
Site of extramedullary diseasea
 Any CNS 0 283 (35)
 Skin only 0 155 (19)
 Lymph node only 0 112 (14)
 Other 0 264 (32)
 Not applicable 8983 0
Time from extramedullary disease to transplant, months N/A 5 (<1–133)
Time from diagnosis to transplant, months 0.21
 Median (range) 6 (<1–321) 7 (<1–200) 0.23
 <6 4188 (47) 360 (44)
 6 – 12 2451 (27) 231 (28)
 >12 2338 (26) 221 (27)
 Missing 6 (<1) 2 (<1)
Conditioning regimen combination <0.001
 MA with TBI 3123 (35) 383 (47)
 MA without TBI 3562 (40) 283 (35)
 RIC/NMA 2298 (26) 148 (18)
Type of donor <0.001
 HLA-identical sibling 3536 (39) 360 (44)
 Well-matched unrelated 3057 (34) 243 (30)
 Partially-matched unrelated 1547 (17) 119 (15)
 Mismatched unrelated 487 (5) 40 (5)
 Unrelated unknown 356 (4) 52 (6)
Graft type 0.97
 Bone marrow 3229 (36) 292 (36)
 Peripheral blood 5754 (64) 522 (64)
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Characteristics of patients No-extramedullary disease Extramedullary P-value
Year of transplant 0.01
 1995–2000 2446 (27) 259 (32)
 2001–2005 3213 (36) 262 (32)
 2006–2010 3324 (37) 293 (36)
Median follow-up of survivors (range), months 60 (3–194) 58 (3–191)
Patients transplanted in CR2 only 1649 200
Duration of CR1, months <0.001
 Median (range) 11 (<1–187) 9 (<1–110) <0.001
 <6 308 (19) 63 (32)
 6 – 12 475 (29) 59 (30)
 >12 631 (38) 53 (27)
 Missing 235 (14) 25 (13)
a
Other sites of extramedullary disease include:
liver/spleen only, n=45; multiple sites, n=69; other specified, n=150
example of other specified: pelvic soft tissue mass; salivary gland chloroma; mass in right lung base; gum pyperplacy ecxema (paws); breast 
infiltrate; left mandible; gastric chloroma; bone (knee); thorencentesis fluid; polychondritis etc.
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